Medpace Holdings, Inc. (MEDP) EBITDA Margin: 22.55%
Is Medpace Holdings, Inc.’s EBITDA margin high or low?
Medpace Holdings, Inc.'s EBITDA margin of 22.55% is in line with its 5-year average of 21.08%, near the high end of its 5-year range (19.22%–23.95%).
As of Wednesday, June 17, 2026. 3.01% below its 12-month average of 23.25%.
MEDP EBITDA Margin Chart
MEDP Average EBITDA Margin Chart
MEDP Current vs Average EBITDA Margin Chart
MEDP EBITDA Margin Metrics
EBITDA MARGIN
22.55%
EBITDA MARGIN AVG TTM
23.25%
EBITDA MARGIN AVG 3Y
21.70%
EBITDA MARGIN AVG 5Y
21.08%
EBITDA MARGIN AVG 10Y
21.60%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-3.01%
CURRENT VS 3Y AVG
+3.89%
CURRENT VS 5Y AVG
+6.96%
CURRENT VS 10Y AVG
+4.39%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | 22.55% | 23.25% | 21.70% | 21.08% |
| Solventum Corporation (SOLV)vs › | $12.91B | 30.62% | 24.56% | 26.05% | 27.07% |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 18.98% | 19.70% | 20.24% | 21.46% |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 25.74% | 26.63% | 26.11% | 26.16% |
| DaVita Inc. (DVA)vs › | $13.46B | 19.37% | 20.32% | 19.37% | 19.72% |
| Revvity, Inc. (RVTY)vs › | $10.91B | 23.20% | 26.85% | 28.84% | 31.56% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Baxter International Inc. (BAX)vs › | $10.19B | 6.81% | 8.65% | 4.13% | 9.00% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 24.97% | 28.56% | 32.04% | 36.42% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 10.23% | 12.29% | 18.59% | 20.64% |
Margin Comparison
Gross Margin
29.1%
EBITDA Margin
22.6%
Operating Margin
21.0%
Net Margin
17.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Medpace Holdings, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Medpace Holdings, Inc. (MEDP)?
- The EBITDA margin for MEDP stock is 22.55%.
- Is Medpace Holdings, Inc.'s EBITDA margin high or low?
- Medpace Holdings, Inc.'s EBITDA margin of 22.55% is in line with its 5-year average of 21.08%, near the high end of its 5-year range (19.22%–23.95%).
- What is the TTM average EBITDA margin for Medpace Holdings, Inc. (MEDP)?
- The TTM average EBITDA margin for MEDP stock is 23.25%.
- What is the 3Y average EBITDA margin for Medpace Holdings, Inc. (MEDP)?
- The 3Y average EBITDA margin for MEDP stock is 21.70%.
- What is the 5Y average EBITDA margin for Medpace Holdings, Inc. (MEDP)?
- The 5Y average EBITDA margin for MEDP stock is 21.08%.
- What is the 10Y average EBITDA margin for Medpace Holdings, Inc. (MEDP)?
- The 10Y average EBITDA margin for MEDP stock is 21.60%.
Medpace Holdings, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 22.55% |
| 2024-12-31 | 23.95% |
| 2023-12-31 | 19.22% |
| 2022-12-31 | 21.10% |
| 2021-12-31 | 19.53% |
| 2020-12-31 | 20.15% |
| 2019-12-31 | 17.47% |
| 2018-12-31 | 19.85% |
| 2017-12-31 | 25.44% |
| 2016-12-31 | 23.59% |
| 2015-12-31 | 24.77% |
| 2014-12-31 | 32.43% |
| 2013-12-31 | 32.12% |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle